Aethlon Medical, Inc. (NASDAQ:AEMD) Stock Short Interest Report for October

Aethlon Medical, Inc. (NASDAQ:AEMD) saw a significant drop in short interest in the month of October. As of October 15th, there was short interest totaling 32,925 shares, a drop of 56.4% from the September 30th total of 75,446 shares. Based on an average daily volume of 57,317 shares, the short-interest ratio is presently 0.6 days. Currently, 4.7% of the shares of the stock are sold short.

Aethlon Medical Price Performance

Aethlon Medical stock traded down $0.08 during midday trading on Friday, reaching $5.44. The company had a trading volume of 27,667 shares, compared to its average volume of 59,298. The company has a market capitalization of $3.87 million, a P/E ratio of -0.16 and a beta of 1.21. Aethlon Medical has a 12-month low of $1.41 and a 12-month high of $26.90. The firm’s fifty day simple moving average is $4.47 and its 200-day simple moving average is $7.79.

Aethlon Medical (NASDAQ:AEMD) last posted its quarterly earnings data on Thursday, August 13th. The medical equipment provider reported ($4.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.92) by ($0.10). On average, analysts expect that Aethlon Medical will post -5.74 EPS for the current fiscal year.

Wall Street Analyst Weigh In

AEMD has been the subject of several research analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aethlon Medical in a research note on Thursday, October 15th. Wall Street Zen upgraded Aethlon Medical to a “sell” rating in a research report on Saturday, October 17th. Finally, HC Wainwright reissued a “neutral” rating on shares of Aethlon Medical in a research note on Friday, September 18th. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Aethlon Medical presently has a consensus rating of “Reduce” and an average price target of $1.50.

Aethlon Medical Company Profile

Aethlon Medical, Inc is a biotechnology and medical-device company focused on developing extracorporeal blood filtration technologies for life-threatening diseases. The company’s lead product candidate, the Hemopurifier, is designed to selectively remove harmful substances from the bloodstream, including cancer-promoting exosomes and certain viral particles.

The Hemopurifier is intended to be used with standard dialysis or blood-circulation equipment and is being investigated for potential applications in oncology and infectious disease.